One of the most significant challenges facing the healthcare system, in addition to continually rising costs, is maintaining high-quality healthcare services. Lean management is a method of organizational management that effectively optimizes processes through continuous improvement and...
Bone is the most common site of distant relapse in breast cancer, and skeletal-related events (SREs) remain a major source of morbidity and reduced quality of life in patients with bone-metastatic disease. Denosumab, a fully human IgG2 monoclonal antibody against receptor activator of nuclear factor-κB ligand (RANKL), interrupts osteoclast-driven bone resorption upstream of the bisphosphonate mechanism of action and has demonstrated superiority over zoledronic acid in preventing SREs in pivotal phase III trials. Beyond this well-established antiresorptive role, RANK/RANKL signaling has been implicated in mammary tumorigenesis and modulation of the tumor immune microenvironment, and recent window-of-opportunity studies have shown that short-term denosumab increases tumor-infiltrating lymphocytes in human breast tumors—a translational finding that has not yet been linked to a demonstrated clinical benefit. This narrative review synthesizes the pharmacology of denosumab; the biological rationale linking RANKL to immune-cell function in the breast; the pivotal and contemporary clinical evidence in metastatic and early breast cancer, including the divergent D-CARE and ABCSG-18 adjuvant trials and the 2026 REDUSE dosing-interval data; and practical considerations distinguishing denosumab’s evidentiary position in metastatic disease, cancer treatment-induced bone loss, and adjuvant disease modification. We also discuss why preclinical immune synergy has not been reproduced clinically and outline priorities for biomarker-selected trials, immunotherapy combinations, dose de-escalation, and MRONJ risk stratification. Throughout, we distinguish established clinical applications from translational and hypothesis-generating findings, and highlight methodological limitations—including small subgroup sizes, retrospective design, and unpublished congress data—that should temper interpretation of several recent findings before they inform clinical practice or future trial design.
5 June 2026 in Advances in Clinical and Experimental Medicine
Hemolytic-uremic syndrome (HUS) is a thrombotic microangiopathy that is most commonly caused by infection with Shiga toxin-producing Escherichia coli (STEC-HUS). Atypical HUS (aHUS) is associated with inappropriate activation of the alternative complement pathway caused by infections, including SARS-CoV-2, malignancies, medications, or other triggering factors in genetically predisposed individuals. Assessment of the impact of the COVID-19 pandemic on epidemiology, course, complications, and outcome of HUS in children in a single tertiary nephrological center in Poland. It is a retrospective study, in which a total number of 74 pediatric patients with HUS were analyzed, including 16 cases in 5-year period before the outbreak of the COVID-19 pandemic (HUS-5) and 58 cases in 5-year period after the outbreak of the pandemic (HUS+5). A more than 3.6-fold increase in HUS cases and a 7-fold higher incidence of STEC-HUS were reported in the HUS+5 population. Strokes and persistent neurological complications were observed only in this group. 91.9% of patients presented with abnormal renal ultrasound (USG) findings at admission, and these findings improved significantly more frequently in the HUS-5 (68.75% vs 25.9%, p = 0.002) group. Mortality did not differ significantly between the 2 analyzed groups and was 6.8% for the entire population. The COVID-19 pandemic has had a significant impact on the incidence of HUS in the pediatric population. SARS-CoV-2 infection most markedly increases the risk of neurological complications but does not affect overall mortality.